Law360, New York (November 10, 2009) -- Threshold Pharmaceuticals Inc. has agreed to pay $10 million to settle a securities fraud action that alleged the biotechnology company and its top executive misled investors ahead of its initial public offering.
The shareholder plaintiffs filed a motion for an order approving the settlement and certifying a class of investors in the U.S. District Court for the Northern District of California on...
